Drug intelligence / Profile preview

VipOS

Development stage: Unknown
Lead developer: Royal Medicalink Pharmalab
Modality: Recombinant Proteins and Enzymes
Administration: Oral

Overview

VipOS (also known as VipAlbumin OS) is a fast-absorbing oral albumin liquid solution developed by Royal Medicalink Pharma for critical care, post-operative recovery, and geriatric nutrition. It is formulated with standardized bioactive extracts of *Channa striata* (snakehead fish, also known as *Ophiocephalus striatus*) and *Curcuma domestica* (turmeric) rhizome. VipOS is designed to rapidly elevate serum albumin and protein levels, maintain plasma colloid oncotic pressure, prevent peripheral edema, and accelerate wound healing in patients recovering from major surgery, critical illness, or suffering from hypoalbuminemia.

Brand names: VipAlbumin OSVipOS
Other names: Channa striata extract + Curcuma domestica extractOphiocephalus striatus extract + Curcuma domestica extract

Beyond the preview

Go deeper on VipOS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VipOS.

Explore the full profile